Elena S Ratner MD
Gynecologic Oncology
Associate Professor, co-Division Director, Gynecologic Oncology,Yale University School of Medicine
Join to view full profile
800 Howard AveYale Physicians Bldg 3RD FLRNew Haven, CT 06519
Phone+1 203-785-4176
Fax+1 203-785-5886
Dr. Ratner is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Elena Ratner is an obstetrician/gynecologist in New Haven, CT and is affiliated with multiple hospitals in the area, including Yale-New Haven Hospital and Lawrence + Memorial Hospital. She received her medical degree from University at Buffalo, School of Medicine and Biomedical Sciences and has been in practice 14 years. She specializes in gynecologic oncology and is experienced in general obstetrics and gynecology and gynecologic oncology.
Education & Training
Yale-New Haven Medical CenterFellowship, Gynecologic Oncology, 2007 - 2010- Yale-New Haven Medical CenterResidency, Obstetrics and Gynecology, 2003 - 2007
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2003
Certifications & Licensure
CT State Medical License 2007 - 2027
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.Alessandro D Santin, Dana M Roque, Eric R Siegel, Victoria M Ettorre, Michelle Greenman
Clinical Cancer Research. 2026-08-03 - Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against-mutated cervical carcinomas with low HER2 expression.Namrata Sethi, Sarah Ottum, Stefania Bellone, Cem Demirkiran, Natalia Buza
Gynecologic Oncology Reports. 2026-08-01 - Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinoma.Sarah Ottum, Namrata Sethi, Stefania Bellone, Cem Demirkiran, Natalia Buza
Gynecologic Oncology. 2026-08-01
Journal Articles
- Phase II Evaluation of Nivolumab in the Treatment of Persistent or Recurrent Cervical Cancer (NCT02257528/NRG-GY002)Alessandro D Santin, Natalia Buza, Samir Khleif, Elena S Ratner, Roisin E O'Cearbhaill, Michael Birrer, Gynecologic Oncology
Press Mentions
“We Need More Advocacy”: Tackling the Biggest Challenges in Ovarian Cancer CareJanuary 23rd, 2026- Why Some Doctors Say There Are Cancers That Shouldn’t Be TreatedDecember 8th, 2025
- Cancer Warning Signs for Women from Yale's Dr. Elena RatnerMarch 17th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
